# Correction: Leung et al. Preclinical Identification of Sulfasalazine’s Therapeutic Potential for Suppressing Colorectal Cancer Stemness and Metastasis through Targeting KRAS/MMP7/CD44 Signaling. Biomedicines 2022, 10, 377

**Authors:** Wai-Hung Leung, Jing-Wen Shih, Jian-Syun Chen, Ntlotlang Mokgautsi, Po-Li Wei, Yan-Jiun Huang

PMC · DOI: 10.3390/biomedicines13030547 · Biomedicines · 2025-02-21

## Full-text entities

- **Genes:** CD44 (CD44 molecule (IN blood group)) [NCBI Gene 960] {aka CDW44, CSPG8, ECM-III, ECMR-III, H-CAM, HCELL}, KRAS (KRAS proto-oncogene, GTPase) [NCBI Gene 3845] {aka 'C-K-RAS, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A}, MMP7 (matrix metallopeptidase 7) [NCBI Gene 4316] {aka MMP-7, MPSL1, PUMP-1}
- **Diseases:** Colorectal Cancer (MESH:D015179), Metastasis (MESH:D009362)
- **Chemicals:** Sulfasalazine (MESH:D012460)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11876789/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC11876789/full.md

## References

1 references — full list in the complete paper: https://tomesphere.com/paper/PMC11876789/full.md

---
Source: https://tomesphere.com/paper/PMC11876789